Clinical trial · Interventional
Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer
A Phase II Trial of Docetaxel/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients, With High-risk Endometrial Carcinoma After Staging Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Previous some studies suggested the addition of chemotherapy to radiation therapy after surgery may have survival benefit in patients with high risk endometrial cancer. In addition, docetaxel plus cisplatin regimen may have similar efficacy with paclitaxel plus carboplatin which is currently used in most cases. However, docetaxel plus cisplatin may cause less toxicity compared to paclitaxel plus carboplatin. Therefore, the investigators aimed to analyze the efficacy of docetaxel plus cisplatin regimen followed by radiation therapy after surgery in patients with high risk endometrial cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Chemotherpay and radiation therapy
- description
- Docetaxel plus cisplatin followed by radiation therapy
- interventionNames
- Drug: Docetaxel
- Drug: Cisplatin
- Radiation: Radiation therapy
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- 2 years after completion of study treatment
Secondary outcomes (3)
- measure
- Overall survival
- timeFrame
- 2 years after completion of study treatment
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * One of following high risk groups Stage III after staging operation Stage II (Type I hysterectomy + BSO + LND) Stage I + two of \[Grade III, LVSI+, Mm\>1/2\] Clear cell or serous carcinoma: stage IB-II * Age: 20-75 * ECOG PS: 0-2 * Adequate organ function BM: WBC ≥ 3,000/mm3, ANC≥1,500/mm3, Plt≥100X103/mm3, Hb≥10.0 g/dl Kidney: Creatinine \<1.25 × UNL이고, GFR ≥ 60 Liver: AST, ALT\< 3×UNL, T- bil\<1.5 mg/ mm3 * Informed Consent Exclusion Criteria: * Previous chemotherapy or pelvic RT * Hormone therapy within 4 weeks * Other malignant disease * Uncontrolled medical disease * Infection requiring antibiotics * Symptomatic CHF, RF, Angina, Arrhythmia, etc. * Neurosis or psychosis * Etc.
References
Publications (0)
Data not yet available